demonstrated that BAP1 null MM had an increased CD8+ T cell infiltration and higher levels of granzyme B transcripts, indicating an active cytotoxic tumor immune microenvironment (TIME), suggesting that MMs with BAP1 loss may be more responsive to immunotherapy (35, 44). The gene discussed is CD8A; the disease is neoplasm.